
Comparative neuropharmacology of structurally distinct non-fentanyl opioids that are appearing on recreational drug markets worldwide
- Author
- Marthe Vandeputte (UGent) , Meng-Hua M. Tsai, Li Chen, Grant C. Glatfelter, Donna Walther, Christophe Stove (UGent) , Lei Shi and Michael H. Baumann
- Organization
- Project
-
- Leave a light on: towards multiplexed luminometric characterization and detection of new psychoactive substances
- True colors are shining through: Flow cytometric biosensors as a new concept in forensic toxicology
- Looks don’t matter, it’s what you do that counts*: Deployment of innovative bio-assays for screening and elucidation of the mechanism of action of new psychoactive substances
- Abstract
- Background: The emergence of novel synthetic opioids (NSOs) is contributing to the opioid overdose crisis. While fentanyl analogs have historically dominated the NSO market, a shift towards non-fentanyl compounds is now occurring.Methods: Here, we examined the neuropharmacology of structurally distinct non-fentanyl NSOs, including U-47700, isotonitazene, brorphine, and N-desethyl isotonitazene, as compared to morphine and fentanyl. Com-pounds were tested in vitro using opioid receptor binding assays in rat brain tissue and by monitoring forskolin-stimulated cAMP accumulation in cells expressing the human mu-opioid receptor (MOR). Compounds were administered subcutaneously to male Sprague-Dawley rats, and hot plate antinociception, catalepsy score, and body temperature changes were measured.Results: Receptor binding results revealed high MOR selectivity for all compounds, with MOR affinities com-parable to those of morphine and fentanyl (i.e., nM). All drugs acted as full-efficacy MOR agonists in the cyclic AMP assay, but nitazene analogs had greater functional potencies (i.e., pM) compared to the other drugs (i.e., nM). When administered to rats, all compounds induced opioid-like antinociception, catalepsy, and body tem-perature changes, but nitazenes were the most potent. Similar to fentanyl, the nitazenes had faster onset and decline of in vivo effects when compared to morphine. In vivo potencies to induce antinociception and catalepsy (i.e., ED50s) correlated with in vitro functional potencies (i.e., EC50s) but not binding affinities (i.e., Kis) at MOR.Conclusions: Collectively, our findings indicate that non-fentanyl NSOs pose grave danger to those individuals who use opioids. Continued vigilance is needed to identify and characterize synthetic opioids as they emerge in clandestine drug markets.
- Keywords
- UND VERWANDTE HETEROCYCLEN, SYNTHETIC OPIOIDS, MORPHINE, RECEPTOR, SYSTEM, Antinociception, cAMP accumulation, Mu-opioid receptor (MOR), Nitazene analogs, Novel synthetic opioids (NSOs), Receptor binding
Downloads
-
Comparative neuropharmacology.docx
- full text (Accepted manuscript)
- |
- open access
- |
- Word
- |
- 700.51 KB
-
(...).pdf
- full text (Published version)
- |
- UGent only
- |
- |
- 1.41 MB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-01HREJKFEK8GEND62084EEQNJD
- MLA
- Vandeputte, Marthe, et al. “Comparative Neuropharmacology of Structurally Distinct Non-Fentanyl Opioids That Are Appearing on Recreational Drug Markets Worldwide.” DRUG AND ALCOHOL DEPENDENCE, vol. 249, 2023, doi:10.1016/j.drugalcdep.2023.109939.
- APA
- Vandeputte, M., Tsai, M.-H. M., Chen, L., Glatfelter, G. C., Walther, D., Stove, C., … Baumann, M. H. (2023). Comparative neuropharmacology of structurally distinct non-fentanyl opioids that are appearing on recreational drug markets worldwide. DRUG AND ALCOHOL DEPENDENCE, 249. https://doi.org/10.1016/j.drugalcdep.2023.109939
- Chicago author-date
- Vandeputte, Marthe, Meng-Hua M. Tsai, Li Chen, Grant C. Glatfelter, Donna Walther, Christophe Stove, Lei Shi, and Michael H. Baumann. 2023. “Comparative Neuropharmacology of Structurally Distinct Non-Fentanyl Opioids That Are Appearing on Recreational Drug Markets Worldwide.” DRUG AND ALCOHOL DEPENDENCE 249. https://doi.org/10.1016/j.drugalcdep.2023.109939.
- Chicago author-date (all authors)
- Vandeputte, Marthe, Meng-Hua M. Tsai, Li Chen, Grant C. Glatfelter, Donna Walther, Christophe Stove, Lei Shi, and Michael H. Baumann. 2023. “Comparative Neuropharmacology of Structurally Distinct Non-Fentanyl Opioids That Are Appearing on Recreational Drug Markets Worldwide.” DRUG AND ALCOHOL DEPENDENCE 249. doi:10.1016/j.drugalcdep.2023.109939.
- Vancouver
- 1.Vandeputte M, Tsai M-HM, Chen L, Glatfelter GC, Walther D, Stove C, et al. Comparative neuropharmacology of structurally distinct non-fentanyl opioids that are appearing on recreational drug markets worldwide. DRUG AND ALCOHOL DEPENDENCE. 2023;249.
- IEEE
- [1]M. Vandeputte et al., “Comparative neuropharmacology of structurally distinct non-fentanyl opioids that are appearing on recreational drug markets worldwide,” DRUG AND ALCOHOL DEPENDENCE, vol. 249, 2023.
@article{01HREJKFEK8GEND62084EEQNJD, abstract = {{Background: The emergence of novel synthetic opioids (NSOs) is contributing to the opioid overdose crisis. While fentanyl analogs have historically dominated the NSO market, a shift towards non-fentanyl compounds is now occurring.Methods: Here, we examined the neuropharmacology of structurally distinct non-fentanyl NSOs, including U-47700, isotonitazene, brorphine, and N-desethyl isotonitazene, as compared to morphine and fentanyl. Com-pounds were tested in vitro using opioid receptor binding assays in rat brain tissue and by monitoring forskolin-stimulated cAMP accumulation in cells expressing the human mu-opioid receptor (MOR). Compounds were administered subcutaneously to male Sprague-Dawley rats, and hot plate antinociception, catalepsy score, and body temperature changes were measured.Results: Receptor binding results revealed high MOR selectivity for all compounds, with MOR affinities com-parable to those of morphine and fentanyl (i.e., nM). All drugs acted as full-efficacy MOR agonists in the cyclic AMP assay, but nitazene analogs had greater functional potencies (i.e., pM) compared to the other drugs (i.e., nM). When administered to rats, all compounds induced opioid-like antinociception, catalepsy, and body tem-perature changes, but nitazenes were the most potent. Similar to fentanyl, the nitazenes had faster onset and decline of in vivo effects when compared to morphine. In vivo potencies to induce antinociception and catalepsy (i.e., ED50s) correlated with in vitro functional potencies (i.e., EC50s) but not binding affinities (i.e., Kis) at MOR.Conclusions: Collectively, our findings indicate that non-fentanyl NSOs pose grave danger to those individuals who use opioids. Continued vigilance is needed to identify and characterize synthetic opioids as they emerge in clandestine drug markets.}}, articleno = {{109939}}, author = {{Vandeputte, Marthe and Tsai, Meng-Hua M. and Chen, Li and Glatfelter, Grant C. and Walther, Donna and Stove, Christophe and Shi, Lei and Baumann, Michael H.}}, issn = {{0376-8716}}, journal = {{DRUG AND ALCOHOL DEPENDENCE}}, keywords = {{UND VERWANDTE HETEROCYCLEN,SYNTHETIC OPIOIDS,MORPHINE,RECEPTOR,SYSTEM,Antinociception,cAMP accumulation,Mu-opioid receptor (MOR),Nitazene analogs,Novel synthetic opioids (NSOs),Receptor binding}}, language = {{eng}}, pages = {{10}}, title = {{Comparative neuropharmacology of structurally distinct non-fentanyl opioids that are appearing on recreational drug markets worldwide}}, url = {{http://doi.org/10.1016/j.drugalcdep.2023.109939}}, volume = {{249}}, year = {{2023}}, }
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: